The off-label use of treatments is especially prevalent in dermatology as the need for effective therapies outpaces the approval process. Experts discuss the most commonly employed treatments, the ethical implications of off-label use, and the need for patient education.
Researchers compared 1-day intravenous dexamethasone pulses with 3-day pulses in a small cohort of children and adolescents with severe AA.
Researchers believe their study to be among the first to show the relationship between the hematologic and inflammatory parameters of alopecia areata and disease severity.
Researchers completed a comprehensive meta-analysis examining existing literature to study the relationship between alopecia areata, anxiety, and depression.
Investigators review the various clinical patterns and trichoscopic, histopathological, and direct immunofluorescence characteristics of nonscarring alopecia in patients with systemic lupus erythematosus and confirm its link to disease activity.
A number of risk factors contribute to the higher mortality rate found in patients with alopecia areata.
Cyclosporin monotherapy was moderately effective at inducing hair regrowth, but the overall response rate did not reach statistical significance.
PF-06700841 and PF-06651600 were found to have an effect onset of 6 and 4 weeks, respectively in patients with moderate to severe alopecia areata.
Poliosis may be induced among elderly persons with AA who have a poor melanocyte reservoir status.
Dupilumab, commonly used for eczema, may be effective for hair regrowth in patients with alopecia totalis and atopic dermatitis.
